Trial Profile
DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DAPASALT
- Sponsors AstraZeneca
- 06 Apr 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 20-Mar-2020), according to European Clinical Trials Database record.
- 14 Dec 2020 Results (n=17) of completed stratum of patients with type 2 diabetes and preserved kidney function, published in the Diabetes Care
- 01 Sep 2020 Results (n=17) presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology.